OptiNose Capex To Revenue vs Total Revenue Analysis

OPTN Stock

USD 0.51 0.02 3.77%

OptiNose financial indicator trend analysis is much more than just breaking down OptiNose prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether OptiNose is a good investment. Please check the relationship between OptiNose Capex To Revenue and its Total Revenue accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.

Capex To Revenue vs Total Revenue

Capex To Revenue vs Total Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of OptiNose Capex To Revenue account and Total Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between OptiNose's Capex To Revenue and Total Revenue is -0.83. Overlapping area represents the amount of variation of Capex To Revenue that can explain the historical movement of Total Revenue in the same time period over historical financial statements of OptiNose, assuming nothing else is changed. The correlation between historical values of OptiNose's Capex To Revenue and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Capex To Revenue of OptiNose are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Capex To Revenue i.e., OptiNose's Capex To Revenue and Total Revenue go up and down completely randomly.

Correlation Coefficient

-0.83

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Total Revenue

Total revenue comprises all receipts OptiNose generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Most indicators from OptiNose's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into OptiNose current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.As of the 26th of November 2024, Selling General Administrative is likely to drop to about 78.7 M. Issuance Of Capital Stock is expected to grow at the current pace this year

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	646K	532K	402K	611.7K
Interest Income	52K	513K	2.5M	2.7M

Depreciation And Amortization Interest Income

OptiNose fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Long Term Debt Total	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab
Total Assets		0.76	0.64	0.37	0.56	0.28	0.95	0.88	0.81	-0.48	-0.58	0.78	0.98	0.54	0.5	0.52	0.74	0.98	0.5	0.58	0.31	0.74	0.56	0.63	0.73	0.67
Short Long Term Debt Total	0.76		0.97	0.75	-0.04	0.7	0.59	0.48	0.75	0.13	-0.93	0.67	0.62	0.63	0.62	0.62	0.99	0.62	0.89	0.87	0.71	0.99	0.42	0.41	0.96	0.99
Other Current Liab	0.64	0.97		0.72	-0.18	0.7	0.46	0.4	0.66	0.27	-0.94	0.59	0.47	0.64	0.63	0.51	0.96	0.47	0.95	0.83	0.72	0.96	0.45	0.35	0.97	0.98
Total Current Liabilities	0.37	0.75	0.72		-0.49	0.91	0.16	0.07	0.49	0.53	-0.9	0.29	0.24	0.37	0.38	0.62	0.73	0.24	0.7	0.95	0.97	0.73	-0.26	0.21	0.74	0.79
Total Stockholder Equity	0.56	-0.04	-0.18	-0.49		-0.56	0.76	0.75	0.32	-0.99	0.33	0.34	0.69	0.13	0.08	0.03	-0.04	0.69	-0.31	-0.3	-0.56	-0.04	0.47	0.42	-0.06	-0.18
Other Liab	0.28	0.7	0.7	0.91	-0.56		0.05	-0.07	0.45	0.62	-0.86	0.39	0.13	0.12	0.14	0.62	0.68	0.13	0.75	0.91	0.91	0.68	-0.16	0.09	0.67	0.75
Net Tangible Assets	0.95	0.59	0.46	0.16	0.76	0.05		0.94	0.72	-0.7	-0.36	0.68	0.98	0.44	0.39	0.41	0.58	0.98	0.27	0.38	0.09	0.58	0.54	0.65	0.57	0.47
Property Plant And Equipment Net	0.88	0.48	0.4	0.07	0.75	-0.07	0.94		0.63	-0.7	-0.29	0.62	0.92	0.43	0.37	0.26	0.47	0.92	0.18	0.28	0.06	0.47	0.54	0.79	0.54	0.37
Current Deferred Revenue	0.81	0.75	0.66	0.49	0.32	0.45	0.72	0.63		-0.25	-0.63	0.56	0.75	0.45	0.42	0.88	0.75	0.75	0.56	0.64	0.44	0.75	0.36	0.45	0.72	0.7
Net Debt	-0.48	0.13	0.27	0.53	-0.99	0.62	-0.7	-0.7	-0.25		-0.41	-0.25	-0.63	-0.08	-0.03	0.01	0.12	-0.63	0.41	0.37	0.6	0.12	-0.39	-0.39	0.14	0.26
Retained Earnings	-0.58	-0.93	-0.94	-0.9	0.33	-0.86	-0.36	-0.29	-0.63	-0.41		-0.51	-0.42	-0.51	-0.51	-0.59	-0.91	-0.42	-0.89	-0.97	-0.9	-0.91	-0.16	-0.33	-0.93	-0.96
Accounts Payable	0.78	0.67	0.59	0.29	0.34	0.39	0.68	0.62	0.56	-0.25	-0.51		0.72	0.32	0.28	0.36	0.63	0.72	0.56	0.5	0.27	0.63	0.62	0.61	0.62	0.61
Cash	0.98	0.62	0.47	0.24	0.69	0.13	0.98	0.92	0.75	-0.63	-0.42	0.72		0.44	0.39	0.46	0.6	1.0	0.3	0.45	0.18	0.6	0.51	0.64	0.58	0.5
Non Current Assets Total	0.54	0.63	0.64	0.37	0.13	0.12	0.44	0.43	0.45	-0.08	-0.51	0.32	0.44		1.0	0.27	0.61	0.44	0.62	0.38	0.25	0.61	0.38	0.32	0.65	0.64
Non Currrent Assets Other	0.5	0.62	0.63	0.38	0.08	0.14	0.39	0.37	0.42	-0.03	-0.51	0.28	0.39	1.0		0.26	0.59	0.39	0.63	0.37	0.26	0.59	0.34	0.28	0.63	0.63
Other Assets	0.52	0.62	0.51	0.62	0.03	0.62	0.41	0.26	0.88	0.01	-0.59	0.36	0.46	0.27	0.26		0.64	0.46	0.5	0.66	0.55	0.64	-0.03	0.24	0.57	0.61
Long Term Debt	0.74	0.99	0.96	0.73	-0.04	0.68	0.58	0.47	0.75	0.12	-0.91	0.63	0.6	0.61	0.59	0.64		0.6	0.87	0.85	0.69	1.0	0.41	0.41	0.96	0.98
Cash And Short Term Investments	0.98	0.62	0.47	0.24	0.69	0.13	0.98	0.92	0.75	-0.63	-0.42	0.72	1.0	0.44	0.39	0.46	0.6		0.3	0.45	0.18	0.6	0.51	0.64	0.58	0.5
Net Receivables	0.5	0.89	0.95	0.7	-0.31	0.75	0.27	0.18	0.56	0.41	-0.89	0.56	0.3	0.62	0.63	0.5	0.87	0.3		0.78	0.68	0.87	0.38	0.17	0.88	0.93
Common Stock Total Equity	0.58	0.87	0.83	0.95	-0.3	0.91	0.38	0.28	0.64	0.37	-0.97	0.5	0.45	0.38	0.37	0.66	0.85	0.45	0.78		0.94	0.85	-0.01	0.33	0.86	0.89
Common Stock Shares Outstanding	0.31	0.71	0.72	0.97	-0.56	0.91	0.09	0.06	0.44	0.6	-0.9	0.27	0.18	0.25	0.26	0.55	0.69	0.18	0.68	0.94		0.69	-0.23	0.26	0.73	0.76
Long Term Debt Total	0.74	0.99	0.96	0.73	-0.04	0.68	0.58	0.47	0.75	0.12	-0.91	0.63	0.6	0.61	0.59	0.64	1.0	0.6	0.87	0.85	0.69		0.41	0.41	0.96	0.98
Non Current Liabilities Total	0.56	0.42	0.45	-0.26	0.47	-0.16	0.54	0.54	0.36	-0.39	-0.16	0.62	0.51	0.38	0.34	-0.03	0.41	0.51	0.38	-0.01	-0.23	0.41		0.27	0.37	0.36
Other Current Assets	0.63	0.41	0.35	0.21	0.42	0.09	0.65	0.79	0.45	-0.39	-0.33	0.61	0.64	0.32	0.28	0.24	0.41	0.64	0.17	0.33	0.26	0.41	0.27		0.53	0.35
Other Stockholder Equity	0.73	0.96	0.97	0.74	-0.06	0.67	0.57	0.54	0.72	0.14	-0.93	0.62	0.58	0.65	0.63	0.57	0.96	0.58	0.88	0.86	0.73	0.96	0.37	0.53		0.96
Total Liab	0.67	0.99	0.98	0.79	-0.18	0.75	0.47	0.37	0.7	0.26	-0.96	0.61	0.5	0.64	0.63	0.61	0.98	0.5	0.93	0.89	0.76	0.98	0.36	0.35	0.96

Click cells to compare fundamentals

OptiNose Account Relationship Matchups

OptiNose fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	172.7M	188.8M	166.1M	144.2M	107.7M	158.3M
Short Long Term Debt Total	75.7M	127.3M	130.7M	131.2M	130.2M	94.0M
Other Current Liab	31.4M	44.6M	49.1M	42.9M	42.4M	29.8M
Total Current Liabilities	36.1M	52.2M	59.2M	178.7M	176.5M	185.4M
Total Stockholder Equity	61.6M	6.8M	(21.8M)	(56.6M)	(86.6M)	(82.3M)
Net Tangible Assets	61.6M	6.8M	(21.8M)	(56.6M)	(65.1M)	(61.9M)
Property Plant And Equipment Net	3.1M	2.0M	1.3M	795K	815K	1.3M
Net Debt	(72.6M)	(19.0M)	20.2M	36.9M	56.5M	59.4M
Retained Earnings	(428.0M)	(527.8M)	(610.1M)	(684.9M)	(720.4M)	(684.4M)
Accounts Payable	3.6M	5.5M	8.0M	5.3M	3.9M	5.6M
Cash	147.1M	144.2M	110.5M	94.2M	73.7M	129.3M
Non Current Assets Total	25.5M	44.7M	5.7M	50.0M	2.4M	2.3M
Non Currrent Assets Other	22.5M	42.6M	4.3M	49.2M	1.6M	1.5M
Other Assets	152K	155K	294K	498K	572.7K	317.1K
Long Term Debt	72.5M	74.5M	125.2M	126.4M	145.4M	78.6M
Cash And Short Term Investments	147.1M	144.2M	110.5M	94.2M	73.7M	129.3M
Net Receivables	13.8M	23.4M	35.4M	33.9M	19.9M	16.1M
Common Stock Total Equity	46K	53K	82K	111K	127.7K	134.0K
Common Stock Shares Outstanding	41.9M	48.3M	56.9M	85.9M	112.1M	117.7M
Long Term Debt Total	72.5M	74.5M	125.2M	126.4M	145.4M	78.6M
Liabilities And Stockholders Equity	172.7M	188.8M	166.1M	144.2M	107.7M	158.3M
Non Current Liabilities Total	74.9M	129.9M	128.6M	22.1M	17.8M	16.9M
Other Current Assets	3.6M	4.1M	2.6M	2.9M	3.7M	4.2M
Other Stockholder Equity	489.6M	534.6M	588.3M	628.2M	633.7M	420.0M
Total Liab	111.1M	182.0M	187.8M	200.8M	194.3M	140.5M
Property Plant And Equipment Gross	3.1M	2.0M	5.6M	5.4M	5.7M	3.5M
Total Current Assets	147.1M	144.2M	160.4M	94.2M	105.3M	139.8M
Accumulated Other Comprehensive Income	(48K)	(85K)	(81K)	(84K)	(96.6K)	(101.4K)
Common Stock	46K	53K	82K	111K	112K	60.0K
Property Plant Equipment	4.4M	2.0M	1.3M	795K	914.3K	868.5K
Inventory	3.5M	9.0M	11.8M	9.4M	8.1M	7.2M
Non Current Liabilities Other	397K	4.7M	2.2M	22.1M	25.4M	26.7M
Capital Surpluse	489.6M	534.6M	588.3M	628.2M	722.5M	557.9M
Net Invested Capital	136.1M	132.0M	104.6M	72.0M	43.6M	41.4M
Net Working Capital	131.9M	128.5M	101.1M	(38.2M)	(71.2M)	(67.6M)

Pair Trading with OptiNose

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if OptiNose position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in OptiNose will appreciate offsetting losses from the drop in the long position's value.

Moving together with OptiNose Stock

0.63	ME	23Andme Holding	Pair Corr
0.91	VALN	Valneva SE ADR	Pair Corr
0.63	VCNX	Vaccinex	Pair Corr

Moving against OptiNose Stock

0.81	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.66	EWTX	Edgewise Therapeutics	Pair Corr
0.65	GILD	Gilead Sciences	Pair Corr
0.5	KZR	Kezar Life Sciences	Pair Corr
0.48	VRDN	Viridian Therapeutics	Pair Corr

The ability to find closely correlated positions to OptiNose could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace OptiNose when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back OptiNose - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling OptiNose to buy it.

The correlation of OptiNose is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as OptiNose moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if OptiNose moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for OptiNose can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether OptiNose offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of OptiNose's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Optinose Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Optinose Stock:

How To Invest In OptiNose

Details

Is OptiNose Stock a good investment?

Details

What is OptiNose's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in OptiNose. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

To learn how to invest in OptiNose Stock, please use our How to Invest in OptiNose guide.

You can also try the Stocks Directory module to find actively traded stocks across global markets.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OptiNose. If investors know OptiNose will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OptiNose listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.29)

Revenue Per Share

0.553

Quarterly Revenue Growth

0.031

Return On Assets

(0.10)

Return On Equity

(10.51)

The market value of OptiNose is measured differently than its book value, which is the value of OptiNose that is recorded on the company's balance sheet. Investors also form their own opinion of OptiNose's value that differs from its market value or its book value, called intrinsic value, which is OptiNose's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OptiNose's market value can be influenced by many factors that don't directly affect OptiNose's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between OptiNose's value and its price as these two are different measures arrived at by different means. Investors typically determine if OptiNose is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OptiNose's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

OptiNose Capex To Revenue vs Total Revenue Analysis

Capex To Revenue vs Total Revenue

Capex To Revenue vs Total Revenue Correlation Analysis

Correlation Coefficient

Capex To Revenue

Total Revenue

OptiNose fundamental ratios Correlations

OptiNose Account Relationship Matchups

High Positive Relationship

High Negative Relationship

OptiNose fundamental ratios Accounts

Pair Trading with OptiNose

Moving together with OptiNose Stock

Moving against OptiNose Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Currrent Assets Other	+ 1.0	Non Current Assets Total
Long Term Debt Total	+ 1.0	Long Term Debt
Long Term Debt	+ 0.99	Short Long Term Debt Total
Long Term Debt Total	+ 0.99	Short Long Term Debt Total
Total Liab	+ 0.99	Short Long Term Debt Total

Net Debt	- 0.99	Total Stockholder Equity
Common Stock Total Equity	- 0.97	Retained Earnings
Total Liab	- 0.96	Retained Earnings
Retained Earnings	- 0.94	Other Current Liab
Other Stockholder Equity	- 0.93	Retained Earnings
Retained Earnings	- 0.93	Short Long Term Debt Total